Nyxoah S.A. (NASDAQ:NYXH) Short Interest Update

Nyxoah S.A. (NASDAQ:NYXH) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 100,200 shares, a growth of 27.2% from the February 13th total of 78,800 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average trading volume of 43,000 shares, the days-to-cover ratio is currently 2.3 days.

Hedge Funds Weigh In On Nyxoah

Several institutional investors and hedge funds have recently modified their holdings of NYXH. Kovack Advisors Inc. purchased a new stake in shares of Nyxoah during the third quarter valued at $96,000. LPL Financial LLC purchased a new position in Nyxoah in the fourth quarter worth about $102,000. Walleye Capital LLC boosted its position in Nyxoah by 23.9% in the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock worth $119,000 after purchasing an additional 2,862 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in Nyxoah in the fourth quarter worth about $135,000. Finally, Geode Capital Management LLC boosted its position in Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock worth $137,000 after purchasing an additional 2,774 shares during the last quarter.

Nyxoah Stock Up 1.8 %

NYXH traded up $0.19 during trading on Tuesday, reaching $10.60. The stock had a trading volume of 70,939 shares, compared to its average volume of 45,072. The stock’s 50 day moving average is $10.30 and its two-hundred day moving average is $9.21. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $361.04 million, a price-to-earnings ratio of -5.67 and a beta of 1.42. Nyxoah has a one year low of $6.76 and a one year high of $20.00.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. As a group, analysts expect that Nyxoah will post -1.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on NYXH shares. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Nyxoah in a research note on Friday, December 13th. Stifel Nicolaus dropped their price target on Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Friday.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.